Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

50.60 +0.04 (+0.09%)

Streaming Delayed Price Updated: 2:29 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

43 44 Next >

Jim Cramer Likes Reddit Very Much, Calls Accenture A 'Great Buy' ↗

October 10, 2024

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Reddit, which went public earlier this year.

Via Benzinga

Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday ↗

October 09, 2024

In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication.

Via The Motley Fool

Topics Lawsuit

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges ↗

October 09, 2024

GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional $70 million set aside for a qui tam case. The company maintains there is no...

Via Benzinga

Topics Lawsuit

Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability ↗

October 08, 2024

Merck faces a class-action lawsuit over alleged misrepresentation of its mumps vaccine potency, claiming anticompetitive practices to maintain market dominance. Despite ethical concerns, the court...

Via Benzinga

Topics Lawsuit

GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons

October 08, 2024

From GSK plc

Via Business Wire

Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated ↗

October 07, 2024

Pfizer sees stock gains following a $1 billion investment by Starboard Value and a favorable UK court ruling invalidating two GSK RSV vaccine patents. Pfizer and GSK continue their legal battles as...

Via Benzinga

Topics Intellectual Property

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 07, 2024

Via Benzinga

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report ↗

October 04, 2024

The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5...

Via Benzinga

Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected ↗

October 03, 2024

Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.

Via Benzinga

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More

October 03, 2024

Via Investor Brand Network

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More

October 03, 2024

EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END

Via FinancialNewsMedia

Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon ↗

October 01, 2024

Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.

Via Benzinga

Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff ↗

September 25, 2024

Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks...

Via Benzinga

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

September 20, 2024

Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment.

Via MarketBeat

Topics Economy

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

September 19, 2024

From Alector, Inc.

Via GlobeNewswire

AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation ↗

September 18, 2024

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial results. The drug showed similar remission rates to GSK's Nucala.

Via Benzinga

GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults ↗

September 18, 2024

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The...

Via Benzinga

GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

September 18, 2024

From GSK plc

Via Business Wire

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths ↗

September 16, 2024

Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test.

Via Investor's Business Daily

Topics Death

Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day ↗

September 13, 2024

The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday.

Via Investor's Business Daily

GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine ↗

September 12, 2024

GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune.

Via Benzinga

GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech ↗

September 11, 2024

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV...

Via Benzinga

FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗

September 06, 2024

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

Via Benzinga

GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug ↗

September 06, 2024

GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks.

Via Benzinga

Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets ↗

August 23, 2024

Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

August 19, 2024

Via Benzinga

Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk ↗

August 16, 2024

A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 15, 2024

Via Benzinga

New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules ↗

August 13, 2024

Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare disease treatment development by imposing stricter guidelines on medical...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

43 44 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.